The Better Care for PFAS Patients Act of 2026 mandates periodic assessments and recommendations on PFAS health effects.
The Better Care for PFAS Patients Act of 2026 requires the Director of the Agency for Toxic Substances and Disease Registry to enter into an agreement with the National Academies of Sciences, Engineering, and Medicine or another appropriate entity. This agreement mandates assessments of the health effects of per- and polyfluoroalkyl substances (PFAS) and clinical recommendations for addressing these effects. The initial assessment and recommendations must be completed within two years of the agreement's entry.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.